Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
37 participants
INTERVENTIONAL
2007-01-22
2007-02-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cumulative Irritation Test
NCT00781664
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
NCT00680160
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
NCT00679601
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
NCT00680134
Study of Different Doses of a Novel Treatment for Onychomycosis
NCT00679965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
AN2690 Solution, 2.5%
AN2690
AN2690 Solution, 2.5%, Daily for up to 21 days
B
AN2690 Solution, 7.5%
AN2690
AN2690 Solution, 7.5%, Daily for up to 21 days
C
AN2690 Solution, 5.0%
AN2690
AN2690 Solution, 5.0%, Daily for up to 21 days
D
AN2690 Solution, Vehicle
AN2690 Solution, Vehicle
AN2690 Solution, Vehicle, Daily for up to 21 days
E
Sodium Lauryl Sulfate, 0.5%
Sodium Lauryl Sulfate, 0.5%
Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AN2690
AN2690 Solution, 2.5%, Daily for up to 21 days
AN2690
AN2690 Solution, 7.5%, Daily for up to 21 days
AN2690
AN2690 Solution, 5.0%, Daily for up to 21 days
AN2690 Solution, Vehicle
AN2690 Solution, Vehicle, Daily for up to 21 days
Sodium Lauryl Sulfate, 0.5%
Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females of childbearing potential submitted to a urine pregnancy test and had negative results at Day 1 and at the final visit and also was using an effective method of birth control (e.g. abstinence, implants, injectables, oral contraceptives, intrauterine contraceptive devices or double barrier) or agreed to use an effective method of birth control prior to becoming sexual active
* Subjects were of any skin type or race providing their degree of pigmentation did not interfere with making readings of skin reactions
* Subjects were willing to follow the study procedures and complete the study
* Written informed consent was obtained
Exclusion Criteria
* Subject was pregnant or nursing
* Subject had a history of sensitivity to any component of any of the formulations
* Use of chronic medications (such as antihistamines, corticosteroids, analgesics and anti-inflammatories) for one week before and during the study
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Education and Research Foundation, Inc.
Lynchburg, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C3371011
Identifier Type: OTHER
Identifier Source: secondary_id
AN2690-ONYC-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.